---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-026324"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T18:52:59.924473+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix raises $325M in private placement; appoints Pravin Dugel as Executive Chairman

## Summary
- Entered securities purchase agreement for 32.4M shares at $7.52/share and pre-funded warrants for 10.8M shares at $7.519/warrant, gross proceeds ~$325M.
- Preliminary unaudited cash $195.8M as of Dec 31, 2023; preliminary FY2023 net product revenue ~$57.9M.
- Pravin Dugel appointed Executive Chairman, effective Feb 21, 2024; receives $540K base salary, equity awards (1.28M options, 855K RSUs).
- CEO Antony Mattessich's employment agreement amended to improve severance benefits; Lead Independent Director Charles Warden appointed.
- Proceeds to accelerate AXPAXLI clinical development for wet AMD, including ongoing SOL-1 and planned SOL-2 Phase 3 trials.

## SEC filing metadata
- accession: 0001104659-24-026324
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/0001104659-24-026324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/tm246953d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-026324
- JSON: https://secwatch.observer/filing/0001104659-24-026324.json
- Plain text: https://secwatch.observer/filing/0001104659-24-026324.txt

## Key facts
- Earnings Releases
  OCULAR THERAPEUTIX, INC reported the quarter and year ended December 31, 2023 results: revenue approximately $57.9 million.
  - Period: the quarter and year ended December 31, 2023
  - Revenue: approximately $57.9 million
  - Result: preliminary results
  source text: its preliminary, unaudited cash and cash equivalents were approximately $195.8 million as of December 31, 2023, and its preliminary, unaudited net product revenue for the year ended December 31, 2023, was approximately $57.9 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/0001104659-24-026324-index.htm
- Executive change
  Pravin U. Dugel, M.D. was appointed as Executive Chairman at OCULAR THERAPEUTIX, INC.
  - Action: appointed
  - Role: Executive Chairman
  source text: On February 20, 2024, Pravin U. Dugel, M.D., was appointed as Executive Chairman of the Company and as a Class III director, effective as of February 21, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/0001104659-24-026324-index.htm
- Material Agreements
  OCULAR THERAPEUTIX, INC entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $325.0 million (effective 2024-02-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional accredited investors
  - Value: approximately $325.0 million
  - Effective: 2024-02-21
  source text: On February 21, 2024, Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 32,413,560 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $7.52 per share and, to certain Investors in lieu of Shares, pre-funded warrants to purchase 10,805,957 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $7.519 per Pre-Funded Warrant (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/0001104659-24-026324-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.